Invacare has signed a consent decree in which the company will fix wheelchair manufacturing problems, the Food and Drug Administration announced. Specifically,  the decree limits the production of custom power and manual wheelchairs, wheelchair components and wheelchair subassemblies at one of the firm’s manufacturing plants. The decree also limits design activities related to wheelchairs and power beds at the Elyria operations. All other Invacare facilities remain in full operation. Invacare said the consent decree is subject to approval of the U.S. District Court for the Northern District of Ohio.